Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.60 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.60 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289632 | 1.00 | PARP10 (1.00) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL11498069 | 0.87 | PARP10 (0.77) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL3133651 | 0.84 | PARP10 (0.73) | PARP10LPAR1LPAR5 | |
| SCHEMBL24209423 | 0.83 | PARP10 (0.70) | PARP10LPAR1LPAR5FEN1 | |
| SCHEMBL9762139 | 0.83 | PARP10 (0.71) | PARP10LPAR1LPAR5 | |
| SCHEMBL9762806 | 0.83 | PARP10 (0.71) | PARP10MAOBLPAR1LPAR5 | |
| SCHEMBL27803784 | 0.82 | PARP10 (0.69) | PARP10PARP15PARP14TNKSTNKS2 | |
| SCHEMBL6293051 | 0.81 | PARP10 (0.66) | PARP10ALDH1A1KMT2ALPAR1LPAR5 | |
| SCHEMBL23463916 | 0.81 | ALDH1A1 (0.68) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL6630817 | 0.81 | PARP10 (0.68) | PARP10PARP15PARP14ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1910374-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007069-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | PARP10 3132/4885PARP15 3852/4885PARP14 4065/4885 |
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | PARP10 3946/4885PARP15 4202/4885PARP14 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.